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Objectives This study assessed whether impaired fasting glucose (IFG), insulin resistance, and waist-to-hip ratio (WHR) had
effects on cardiac remodeling, independent of obesity, in the MESA (Multi-Ethnic Study of Atherosclerosis) trial.
Background Recent studies have suggested that central obesity and insulin resistance may be primary mediators of obesity-
related cardiac remodeling independent of body mass index (BMI).
Methods We investigated 4,364 subjects without diabetes in the MESA trial. IFG (100 to 125 mg/dl) or insulin resistance
(by homeostatic model assessment of insulin resistance [HOMA-IR]) and WHR were used for cardiometabolic
phenotyping. Multivariate linear regression analysis was used to determine the effects of the cardiometabolic
markers on left ventricular (LV) remodeling, assessed primarily through the LV mass-to-volume ratio obtained by
cine cardiac magnetic resonance imaging.
Results Individuals with IFG were more likely to be older and hypertensive, with increased prevalence of cardiometabolic
risk factors regardless of BMI. In each quartile of BMI, subjects with above-median HOMA-IR, above-median
WHR, or IFG had a higher LV mass-to-volume ratio (p  0.05 for all). HOMA-IR (p  0.0001), WHR (p  0.0001),
and the presence of IFG (p  0.04), but not BMI (p  0.24), were independently associated with LV mass-to-
volume ratio after adjustment for age, sex, hypertension, race, and dyslipidemia.
Conclusions Insulin resistance and WHR were associated with concentric LV remodeling independent of BMI. These results sup-
port the emerging hypothesis that the cardiometabolic phenotype, defined by insulin resistance and central obesity,
may play a critical role in LV remodeling independently of BMI. (J Am Coll Cardiol 2013;61:1698–706) © 2013 by
the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.053Affecting nearly 1 in 3 adults, obesity represents a growing
critical risk to cardiovascular health (1). With associated
abnormalities in left and right ventricular structure and
function (2), obesity imposes a higher lifetime risk of heart
failure independent of comorbid illnesses (hypertension,
coronary artery disease, and type 2 diabetes) (3–5). Recently,
abnormal neurohormonal activation from visceral adipocyte
stores has been postulated to drive insulin resistance and
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#Department of Radiology, Brigham and Women’s Hospital, Harvard Medicalproinflammatory metabolic syndrome, linking obesity to
heart failure (6). In effect, the insulin resistance that
accompanies central obesity (“adiposopathy”) has been pro-
posed to resolve an “obesity paradox,” the observation that
not all obese individuals are subject to similarly elevated
cardiovascular risk (6). In several large studies, markers of
central obesity and insulin resistance, but not body mass
index (BMI), predicted cardiac mortality and heart failure,
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April 23, 2013:1698–706 Obesity, IR, and LV Remodeling in the MESA Trialeven with normal BMI (7–12). The hypothesized role of
insulin resistance independent of BMI has recently given
rise to the concept of a “metabolically healthy” obese and
“metabolically unwell” nonobese individual. Indeed, obese
individuals without other components of metabolic syndrome
have a lower lifetime heart failure risk, compared with nono-
bese individuals with metabolic syndrome (9). However,
hether presence of central obesity and insulin resistance is
ssociated with adverse cardiac remodeling independent of
MI in patients without diabetes or established cardiovascular
isease is unknown.
To provide evidence to support the effect of insulin resis-
ance on cardiac remodeling across BMI, we investigated
arkers of insulin resistance, central obesity, and ventricular
tructure and function in participants of the MESA (Multi-
thnic Study of Atherosclerosis) trial. Using a cross-sectional
esign, we tested whether insulin resistance and waist-to-hip
atio (WHR) are associated with concentric left ventricular
LV) remodeling (as defined by LV mass-to-volume ratio)
ndependent of BMI. Given the important links between
nflammation and cardiovascular disease across BMI, we fur-
her tested the hypothesis that systemic inflammation is asso-
iated with concentric LV remodeling, independent of BMI,
nsulin resistance, or WHR.
ethods
articipant population. The overall design of the MESA
tudy has been described previously (13). In brief, the
ESA study consisted of 6,814 men and women of
ifferent ethnicities (white, African American, Chinese
merican, and Hispanic) enrolled from 6 different national
ites, all of whom were free of clinical cardiovascular disease
history of myocardial infarction, angina pectoris, previous
evascularization, heart failure, atrial fibrillation, stroke, or
eripheral arterial disease) at the time of enrollment. Base-
ine demographics and medical history (including cardiac
isk factors), as well as height, weight, and waist and hip
imensions, were collected at the index examination (July
000 to August 2002 cycle). BMI was calculated as weight
ivided by the square of height (in kg/m2). Resting systolic
lood pressure was measured 3 times in the seated position
sing a Dinamap Pro 100 sphygmomanometer (Critikon,
ipro GE Healthcare, Waukesha, Wisconsin). Fasting
lood glucose (Vitros analyzer, Johnson and Johnson Clin-
cal Diagnostics, Rochester, New York) and fasting insulin
human insulin-specific radioimmunoassay kit, Linco Re-
earch, St. Charles, Missouri) levels were assessed during
he baseline visit. In addition, selected biomarkers of in-
ammation, including interleukin (IL)-6, C-reactive pro-
ein (CRP), tumor necrosis factor (TNF)-alpha receptor 1,
nd plasminogen activator inhibitor (PAI)-1, and cardiac
emodeling were collected, as previously described (14).
ours of physical activity per week were extracted from
elf-reported questionnaires conducted at the initial study
isit. Protocols were approved by the institutional review coard at each participating insti-
ution. All participants provided
ritten informed consent.
From the initial sample enrolled
n the first MESA examination
N  6,814), subjects with data
issing for fasting blood glucose,
MI, or waist or hip circumfer-
nce (n  26 [0.4%]) were ex-
luded. In addition, subjects with
iabetes mellitus (defined by a
asting blood sugar126 mg/dl at
creening, history of treated or un-
reated diabetes, or use of antidia-
etic medications) were excluded
n  925), leaving 5,863 subjects
ith complete data on adiposity
easures and fasting blood glucose
ithout established diabetes.
ardiac magnetic resonance
ssessment of LV structure and
unction. Cardiac magnetic reso-
ance imaging (MRI) was per-
ormed at 1.5-T at the index ex-
mination as previously described (15,16). Assessment of
entricular function was performed using electrocardiographi-
ally gated fast-gradient echo cine images (repetition time 6
s, minimal echo time, flip angle 20°, 8-mm slice thickness
ith 2-mm gap, matrix 256  160, field of view adjusted to
ody size, receiver bandwidth 32 kHz). LV volumes and mass
ere determined by short-axis volumetric coverage, normalized
o body surface area. Papillary muscles were included in the LV
olumes and excluded from LV mass. LV mass to LV
nd-diastolic volume was calculated as an index of concentric
emodeling.
For analysis of regional myocardial systolic and diastolic
unction, cardiac MRI tagging and regional systolic wall
hortening analyses were performed in a subgroup of the
opulation (17). Global systolic wall shortening was calcu-
ated for the mid-LV short-axis slice as the average of
egmental fractional shortening: (LV end-diastolic  LV
nd-systolic)/LV end-diastolic thickness (n  4,215). Car-
iac MRI tagging analysis was performed with 2 sets of cine
mages with spatially modulated magnetization in orthogo-
al directions, using 7-mm tag line spacing, and analyzed by
armonic phase techniques (HARP software, Diagnosoft,
orrisville, North Carolina) over 19 to 27 phases/cardiac
ycle (average repetition time 6 ms, echo time 3 ms, flip
ngle 12°, matrix 256  96 to 140, average temporal
esolution 40 ms). Peak systolic strain (marker of subclinical
entricular systolic dysfunction) was calculated as the aver-
ge of segmental peak systolic strain in the mid-LV slice
n 880). MASS software (version 4.2, Medis, Leiden, the
etherlands) was used to quantify data at a single reading
Abbreviations
and Acronyms
BMI  body mass index
CRP  C-reactive protein
HDL  high-density
lipoprotein
HOMA-IR  homeostatic
model assessment of
insulin resistance
IFG  impaired fasting
glucose
IL  interleukin
LV  left ventricular
MRI  magnetic resonance
imaging
PAI  plasminogen
activator inhibitor
MRI  magnetic resonance
imaging
TNF  tumor necrosis
factor
WHR  waist-to-hip ratioenter by readers blinded to clinical data.
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Obesity, IR, and LV Remodeling in the MESA Trial April 23, 2013:1698–706Statistical analysis. We examined impaired fasting glucose
(IFG) (100 to 125 mg/dl) and insulin resistance (by homeo-
stasis model assessment of insulin resistance [HOMA-IR];
fasting insulin in U/ml  fasting glucose in mg/dl / 405)
18). We assessed central obesity by WHR. Baseline clini-
al, demographic, and measures of ventricular structure/
unction were stratified by obesity (BMI30 kg/m2) and by
IFG. Data normality was assessed by visual inspection of
distributions and normal quantile-quantile plots. The Stu-
dent t test (normal continuous data) or Kruskal-Wallis test
(non-normal continuous data) was used for comparisons.
Chi-square or Fisher exact tests were used for categorical
covariates. Biomarker concentrations were compared by
nonparametric (Wilcoxon rank-sum) testing.
The association of insulin resistance and central obesity
with cardiac structure was assessed by Spearman correlation
between cardiac MRI LV structure and function and
HOMA-IR, WHR, or fasting glucose in the whole popu-
lation and in obese and nonobese individuals separately. To
examine the association of HOMA-IR or WHR with
concentric LV remodeling, we compared the LV mass-to-
volume ratio across quartiles of BMI, stratified around
median HOMA-IR, median WHR, or presence of IFG.
Two-way analysis of variance and post hoc Student t tests
(with Bonferroni correction for multiple hypothesis testing)
were used to compare across strata.
To investigate how insulin resistance or central obesity
modified the association between BMI and LV mass-to-
volume ratio, we built a multivariate linear regression model
with LV mass-to-volume ratio as the dependent variable
and BMI (continuous variable), presence of IFG,
HOMA-IR (dichotomized by median), and WHR (dichot-
omized by median) included as explanatory variables, as well
as interaction terms of each marker (IFG, HOMA-IR, or
WHR) with BMI. We also adjusted for age, sex, race,
previous and current smoking status, history of hypertension
(by Joint National Committee VI guidelines), high-density
lipoprotein levels, and triglyceride levels in the model
(hereafter referred to collectively as “clinical covariates”).
Continuous variables (age, triglycerides, high-density lipo-
protein [HDL], and BMI) were centered and standardized
in this model. A separate model (without the interactions)
was constructed to check the stability of the main effects.
We examined associations between LV mass-to-volume
ratio, a marker of concentric LV remodeling, and inflam-
matory biomarkers. For all regression analyses, biomarkers
of systemic inflammation were log-transformed to establish
normality. Spearman correlation coefficients were used to
measure association of inflammatory biomarkers with BMI,
fasting glucose, HOMA-IR, and WHR in the overall
population and in the obese and nonobese groups separately.
PAI-1 levels are known to be elevated in obesity and
metabolic syndrome, and its relationship with the cardiometa-
bolic phenotype markers and the LV structure parameters was
closely examined. To assess whether HOMA-IR or WHR
would affect the relationship between PAI-1 and obesity, wecompared mean PAI-1 levels with 2-way analysis of variance
across quartiles of BMI, with PAI-1 stratified by median
HOMA-IR or WHR. Student t tests (with Bonferroni cor-
rection for multiple hypothesis testing for 4 comparisons, one
for each quartile) were used for post hoc comparisons. The
effect of PAI-1 on concentric LV remodeling was assessed
with a linear regression model for LV mass-to-volume ratio,
with PAI-1 (log-transformed), HOMA-IR, WHR, IFG, and
BMI as predictors, and simultaneous adjustment by clinical
covariates. To examine links between PAI-1 and cardiometa-
bolic markers, we also built a model for PAI-1 that included
BMI, HOMA-IR (dichotomized by median), WHR (dichot-
omized by median), IFG, and the interaction of each param-
eter with BMI as predictors. Continuous variables were cen-
tered and standardized. The number of measurements for each
analysis varied, based on the availability of cardiac MRI data. A
value of p  0.05 was considered significant. Analyses were
performed using SAS version 9.3 (SAS Institute, Cary, North
Carolina) or R (version 2.15.1, R Foundation for Statistical
Computing, Vienna, Austria).
Results
Clinical and biochemical characteristics by obesity and
IFG. Baseline clinical, demographic, and biochemical
characteristics of the study population are shown in Table 1.
Of the overall population, 1,734 (30%) were obese by BMI
criteria. In the obese subgroup, 386 subjects (22%) had IFG, as
compared with 515 subjects (12%) with IFG in the nonobese
stratum (p  0.0001). The presence of IFG in both the
nonobese and obese groups was associated with a more adverse
clinical, metabolic, and inflammatory profile. Compared with
subjects without IFG, subjects with IFG (in both obese and
nonobese groups) were older, more often male, and more often
hypertensive, with a greater waist circumference, WHR, HDL
and triglyceride concentrations, fasting glucose level, and
HOMA-IR. In addition, markers of systemic adiposity-related
inflammation (e.g., CRP, PAI-1, IL-6, soluble TNF-alpha
receptor-1, urine albumin) were higher in the obese group and
in subjects with IFG. In addition, there was a statistically
significant increase in prevalence of IFG across quartiles of
HOMA-IR and WHR in both the obese and nonobese
cohorts (p  0.05 for all panels) (Fig. 1). Finally, a greater
proportion of obese subjects did not engage in any weekly
exercise (27% vs. 20% in nonobese, p  0.0001) (Table 1).
Subjects with IFG exercised less per week as compared with
those with normal fasting glucose, regardless of obesity status
(p  0.001). Obese subjects with IFG had a lower amount of
weekly intentional exercise than those with normal fasting
glucose (p  0.006).
Association among insulin resistance, central obesity, and
LV remodeling in obese and nonobese subjects. Cardiac
MRI indexes of LV remodeling and systolic function,
stratified by obesity and IFG, are shown in Table 2.
Regardless of obesity status, subjects with IFG had a higher
LV mass-to-volume ratio, higher ventricular mass index,
Baseline Demographic, Clinical, and Biochemical Characteristics, Stratified by NFG or IFG and by BMITable 1 Baseline Demographic, Clinical, and Biochemical Characteristics, Stratified by NFG or IFG and by BMI
Variable
BMI <30 kg/m2 (n  4,129) BMI >30 kg/m2 (n  1,734)
Obese vs. Nonobese
(p Value)
NFG (n  3,614) IFG (n  515) p Value NFG (n  1,348) IFG (n  386) p Value NFG IFG
Age, yrs 61.9 10.5 65.8 9.7 0.0001 59.9 9.7 62.2 9.6 0.0001 0.0001 0.0001
Male 1,697 (47) 321 (62) 0.0001 521 (39) 185 (48) 0.001 0.0001 0.0001
BMI, kg/m2 25.1 2.9 26.3 2.6 0.0001 34.2 4.0 35.1 4.4 0.0007 0.0001 0.0001
Systolic blood pressure, mm Hg 123.5 20.8 131.5 21.9 0.0001 128.7 20.3 133.5 19.6 0.0001 0.0001 0.15
Hypertension 1,279 (35) 267 (52) 0.0001 655 (49) 232 (60) 0.0001 0.0001 0.01
Current or former smoker 1,762 (49) 250 (49) 0.96 686 (51) 195 (51) 1.0 0.17 0.52
Race 0.0001 0.004 0.0001 0.0001
Caucasian 1,638 (45) 167 (32) 517 (38) 115 (30)
Chinese American 538 (15) 124 (24) 19 (1) 11 (3)
African American 764 (21) 115 (22) 496 (37) 150 (39)
Hispanic 674 (19) 109 (21) 316 (23) 110 (29)
Metabolic syndrome
Waist circumference, cm 90.3 10.0 95.2 8.6 0.0001 110.9 11.2 114.4 11.8 0.0001 0.0001 0.0001
Waist-to-hip ratio 0.91 (0.85–0.96) 0.95 (0.91–0.99) 0.0001 0.96 (0.90–1.00) 0.98 (0.93–1.01) 0.0001 0.0001 0.0001
HDL, mg/dl 53.9 15.6 48.2 13.5 0.0001 48.8 13.2 45.7 11.1 0.0001 0.0001 0.002
Triglycerides, mg/dl 102.0 (72.0–145.0) 126.0 (87.0–173.0) 0.0001 118.0 (83.0–168.0) 131.0 (88.0–185.0) 0.004 0.0001 0.32
Weight, kg 70.3 12.3 74.0 11.9 0.0001 94.5 14.1 96.9 14.3 0.003 0.0001 0.0001
Fasting glucose, mg/dl 85.7 7.1 107.1 6.9 0.0001 87.6 6.7 108.1 7.0 0.0001 0.0001 0.02
Fasting insulin, U/ml 6.65 (5.15–9.02) 9.64 (7.02–12.89) 0.0001 10.6 (7.8–14.5) 13.9 (10.8–18.9) 0.0001 0.0001 0.0001
HOMA-IR 1.41 (1.07–1.95) 2.50 (1.89–3.38) 0.0001 2.28 (1.66–3.19) 3.65 (2.87–5.09) 0.0001 0.0001 0.0001
Intentional weekly exercise,
METs-min/week
990 (210–2,235) 840 (210–2,062.5) 0.40 667 (0–1,777.5) 510 (0–1,410) 0.006 0.0001 0.0001
Biomarkers
Estimated GFR, ml/min/1.73 m2 78.9 (69.4–90.4) 79.3 (69.1–91.2) 0.36 79.4 (69.3–91.3) 80.4 (67.6–93.1) 0.19 0.87 0.49
Urine albumin present 192 (5) 55 (11) 0.0001 99 (7) 50 (13) 0.0001 0.006 0.29
NT-proBNP, pg/ml 58.6 (27.8–115.7) 52.2 (22.8–108.5) 0.02 51.4 (20.4–107.0) 42.7 (20.9–89.6) 0.13 0.0001 0.11
C-reactive protein, mg/l 1.34 (0.62–3.06) 1.65 (0.81–3.53) 0.0001 3.22 (1.56–6.78) 4.05 (1.92–7.40) 0.01 0.0001 0.0001
PAI-1, ng/ml 14.0 (8.0–25.0) 25.0 (17.0–41.5) 0.0001 24.5 (13.0–48.0) 39.5 (24.0–71.5) 0.0001 0.0001 0.001
MMP3, ng/ml 12.2 (8.3–19.1) 14.6 (10.4–21.4) 0.07 10.8 (7.6–16.0) 9.4 (7.5–15.2) 0.36 0.03 0.003
MMP9, ng/ml 207.1 (151.4–292.3) 184.1 (134.9–254.5) 0.23 228.3 (157.6–333.7) 239.2 (176.7–315.0) 0.79 0.04 0.04
IL-6, pg/ml 0.97 (0.66–1.54) 1.21 (0.81–1.85) 0.0001 1.53 (1.05–2.28) 1.74 (1.21–2.74) 0.0001 0.0001 0.0001
TNF-alpha receptor 1, pg/ml 1,243 (1,063–1,469) 1,287 (1,109–1,565) 0.03 1,345 (1,176–1,554) 1,416 (1,222–1,652) 0.04 0.0001 0.0008
Values are mean  SD, n (%), or median (interquartile range). Normal variables were compared using the Student t test, and non-normal variables were compared using a Wilcoxon (Kruskal-Wallis) test. Categorical variables were compared using chi-square (for 2  2
comparisons) or Fisher exact tests (otherwise).
BMI  body mass index; GFR  glomerular filtration rate; HDL  high-density lipoprotein; HOMA-IR  homeostatic model assessment of insulin resistance; IFG  impaired fasting glucose; IL  interleukin; MET metabolic equivalent; MMP matrix metalloproteinase;
NFG  normal fasting glucose; NT-proBNP  N-terminal pro–B-type natriuretic peptide; PAI  platelet activator inhibitor; TNF  tumor necrosis factor.
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Obesity, IR, and LV Remodeling in the MESA Trial April 23, 2013:1698–706and lower end-diastolic volume index. In the overall cohort,
higher fasting glucose, HOMA-IR, BMI, and WHR were
all positively associated with concentric LV remodeling (all
p  0.0001) (Online Table 1). Markers of cardiometabolic
health (IFG, WHR) also had an effect on regional LV
function: in both the obese and nonobese groups, subjects
with IFG had a small reduction in peak systolic strain
(Table 2). A less negative peak systolic strain (denoting
subclinical systolic dysfunction) was associated with a higher
fasting glucose (p  0.01), HOMA-IR, BMI, and WHR
p  0.0001 for all) (Online Table 1). When limited to
atients with IFG, male sex (beta  1.93; p  0.0001) and
igher BMI (beta  0.14; p  0.01) were associated with
ower peak systolic strain, after adjustment for age, sex, race,
istory of hypertension, triglyceride levels, BMI, HDL
holesterol levels, and log-transformed HOMA-IR.
ncremental effects of insulin resistance and central
besity on concentric LV remodeling across BMI. When
tratified by quartiles of BMI, LV mass-to-volume ratio was
Figure 1 Prevalence of IFG Stratified by BMI and Waist-to-Hip R
Distribution of impaired fasting glucose (IFG) (open bars) and normal fasting gluco
and nonobese (BMI 30 kg/m2) (B and D) strata and quartiles of waist-to-hip ratiignificantly higher in subjects with IFG, above-median rOMA-IR (HOMA-IR 1.73), and above-median
HR (WHR 0.92) (Fig. 2). Consistently, subjects with
bove-median WHR, HOMA-IR, or IFG had greater LV
ass-to-volume ratio at every quartile of BMI. When
OMA-IR was stratified around 2.5 (as has been reported
19]), HOMA-IR continued to have a highly significant
ssociation with LV mass-to-volume ratio across BMI
uartiles (p  0.0001).
Table 3, with the regression coefficients of a multivariate
inear regression model for LV mass-to-volume ratio, dem-
nstrates the association of LV mass-to-volume ratio with
he cardiometabolic predictors (HOMA-IR, WHR, or
FG). In this model, BMI was not significantly associated
ith LV mass-to-volume ratio. In addition, BMI did not
odify the association of HOMA-IR with LV mass-to-
olume (p  0.77), suggesting that above-median
OMA-IR was associated with concentric LV remodeling
egardless of BMI. In contrast, BMI did modify the
ssociation of WHR (p  0.008) with LV mass-to-volume
lid bars) across obese (body mass index [BMI] 30 kg/m2) (A and C)
omeostatic model assessment of insulin resistance (HOMA-IR).atio
se (so
o or hatio, suggesting that a higher WHR may have a greater
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April 23, 2013:1698–706 Obesity, IR, and LV Remodeling in the MESA Trialimpact on concentric LV remodeling in more obese sub-
jects. In a model without interaction terms adjusted for clinical
covariates, HOMA-IR (beta  0.0205; p  0.0001), WHR
(beta  0.0247; p  0.0001), and IFG (beta  0.0243; p 
.02), but not BMI (p  0.10), were still each independently
ssociated with LV mass-to-volume ratio.
ssociation of biomarkers of inflammation with concentric
emodeling. Spearman correlations between inflammatory
iomarkers and LV-mass-to-volume ratio, HOMA-IR,
Figure 2 LV Remodeling as a Function of Cardiometabolic Risk
Left ventricular (LV) mass-to-volume ratio across quartiles of BMI, stratified by abo
Error bars represent 95% CI of the mean. Comparisons across HOMA-IR, WHR, or
hypothesis testing). NFG  normal fasting glucose; other abbreviations as in Figur
Ventricular Remodeling and Regional Function by Cardiac MRI, StrTable 2 Ventricular Remodeling and Regional Function by Card
Variable
BMI <30 kg/m2
NFG IFG (N
Ventricular remodeling (n  4,364)
LV ejection fraction, % 69.1 7.1 69.4 8.1
LV end-diastolic volume index, ml/m2 69.0 13.8 65.9 13.2
LV end-systolic volume index, ml/m2 21.6 8.0 20.5 8.2
LV mass index, g/m2 76.5 16.1 78.3 14.6
LV mass-to-volume ratio 1.13 0.22 1.22 0.25
Regional function (mid-LV)
Systolic wall shortening, % (n  4,215) 78.1 26.9 77.4 27.2
Peak systolic strain, % (n  880) 17.6 2.4 17.0 2.7
Values are mean  SD. Strain data were calculated as a segmental average in the midventricul
compared with Student t test.
LV  left ventricular; MRI  magnetic resonance imaging; other abbreviations as in Table 1.HR, and fasting glucose level are shown in Online Table 2
or the overall population and stratified by obesity. Although
ll inflammatory markers were associated with LV mass-to-
olume ratio (in both obese and nonobese subjects), PAI-1
emonstrated a consistent, significant association with concen-
ric LV remodeling, insulin resistance, and central obesity and
as therefore selected for further analyses.
PAI-1 levels were higher in subjects with above-median
OMA-IR across quartiles of BMI (Fig. 3). In a multi-
Obesity
d below-median HOMA-IR or waist-to-hip ratio (WHR) and the presence of IFG.
oups were made by Student t tests (with Bonferroni adjustment for multiple
p  0.05. **p  0.01. ***p  0.001.
d by BMI and NFG or IFGRI, Stratified by BMI and NFG or IFG
BMI >30 kg/m2
Obese vs.
Nonobese
(p Value)
ue
. IFG) NFG IFG
p Value
(NFG vs. IFG) NFG IFG
69.0 7.0 68.6 7.8 0.55 0.56 0.24
01 68.0 13.0 65.4 12.1 0.005 0.06 0.59
21.3 7.5 20.7 7.6 0.24 0.43 0.76
78.0 15.2 82.5 18.7 0.0009 0.009 0.004
01 1.17 0.24 1.28 0.27 0.0001 0.0001 0.002
77.7 26.5 75.8 29.0 0.36 0.66 0.50
17.0 2.8 16.1 3.1 0.04 0.01 0.05
. The number of observations available in the whole population are as indicated. Variables wereand
ve- an
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transformed), containing similar covariates as in the model
in Table 3 (without interaction terms), BMI (p  0.0001),
HOMA-IR (p  0.0001), and WHR (p  0.04), but not
IFG (p  0.64), were associated with PAI-1. When PAI-1
was added as predictor to the model for LV mass-to-volume
ratio (including covariates in Table 3, without interactions),
PAI-1 had a significant association with concentric LV
remodeling (beta  0.0226; p  0.04), independent of
BMI, WHR, HOMA-IR, and other clinical covariates. Of
note, WHR (p  0.001) and IFG (p  0.01) maintained a
ignificant association with concentric LV remodeling in
his model. It should be noted that removal or addition of
AI-1 as a predictor in the linear regression model for LV
ass-to-volume ratio did not cause the other predictors to
ose or gain statistical significance, yet the addition of PAI-1
s a predictor resulted in a significantly (p  0.038) better
greement with the data than the model without PAI-1.
iscussion
n this cross-sectional, multiethnic, community-based
tudy, the presence of insulin resistance (by HOMA-IR)
nd central obesity (by WHR) was associated with concen-
ric LV remodeling across the spectrum of BMI. IFG
dentified a subgroup within both obese and nonobese
ndividuals with a higher cardiometabolic risk (by metabolic
yndrome criteria) and greater concentric LV remodeling.
Table of Regression Coefficients From a MultivariateLinear Regression Mod l for LV Mass-to-Volume RatioTable 3 Table of R gression Coefficients From a MultivariateLinear Regression Model for LV Mass-to-Volume Ratio
Covariate
Model Parameters
Beta p Value
Age 0.0424 0.0001
Male 0.105 0.0001
Hypertension 0.0623 0.0001
Smoking
Past 0.00822 0.25
Current 0.0705 0.0001
Triglyceride level 0.00455 0.21
HDL level 0.00505 0.21
Race*
Chinese 0.00730 0.50
African American 0.0724 0.0001
Hispanic 0.000888 0.92
BMI 0.00581 0.24
HOMA-IR 0.0198 0.0001
BMI  HOMA-IR (interaction) 0.00119 0.77
WHR 0.0258 0.0001
BMI  WHR (interaction) 0.00956 0.008
Presence of IFG 0.0207 0.04
BMI  IFG (interaction) 0.0161 0.13
Model was constructed with BMI, age, male sex, history of hypertension, triglycerides, HDL, race,
BMI, HOMA-IR, WHR, IFG, and interactions between insulin resistance and visceral adiposity with
BMI as predictors. Continuous variables (age, triglycerides, HDL, and BMI) were centered and
standardized for inclusion as predictors. The R2 for this multivariable model is 0.22.
WHR  waist-to-hip ratio; other abbreviations as in Tables 1 and 2.FG, higher HOMA-IR, and higher WHR were signifi- dantly associated with concentric LV remodeling, after
djustment for BMI and clinical covariates. After adjust-
ent for clinical covariates (as well as HOMA-IR, WHR,
nd IFG), BMI was not associated with LV mass-to-
olume ratio, suggesting that insulin resistance may explain
ome of the effect of BMI on concentric LV remodeling in
ndividuals without established diabetes or cardiovascular
isease. These results highlight the importance of insulin
esistance and central obesity in the pathogenesis of con-
entric LV remodeling across BMI.
Current World Health Organization guidelines define
obesity” as BMI 30 kg/m2 (20). However, a growing
iterature supports inflammation and insulin resistance as a
otential etiology for cardiovascular damage in both “obese”
nd “nonobese” subjects (6). Proinflammatory visceral adi-
ocytes produce a variety of neurohormonal signals, including
L-6 and PAI-1 (6), which mediate hepatic insulin resistance
21), cardiac remodeling, and heart failure (22,23). In fact,
ardiovascular function and clinical outcomes are associated
ith the extent and neurohormonal activity of visceral fat
7,8,11,24), such that obese subjects without proinflammatory
isceral adipose tissue remain metabolically neutral (25). Ulti-
ately, cardiovascular risk may depend more on insulin resis-
ance than on BMI (26), with insulin resistance driving
ncident heart failure in nonobese subjects to a greater degree
han in metabolically healthy obese subjects (9). Our results
upport the emerging hypothesis that “adiposopathy”
marked by insulin resistance and visceral adipose distribu-
ion) impacts cardiac remodeling across BMI beyond mark-
rs of clinical risk. These results are in agreement with a
ecent smaller study using echocardiography, demonstrating
relationship among ventricular function, CRP, and
OMA-IR in patients with normal-weight obesity (normal
MI, increased fat content) (27).
Our results provide additional insight into relationships
mong inflammation, insulin resistance, and remodeling.
AI-1 exhibited a significant association with HOMA-IR
nd WHR in the overall cohort and in both obese and
onobese strata, again confirming a connection among
diposopathy, inflammation, and systemic insulin resistance
28,29). When adjusted for clinical covariates, HOMA-IR,
MI, and WHR were all significantly associated with
AI-1 levels. Furthermore, PAI-1 was associated with
oncentric LV remodeling beyond that predicted by BMI,
nsulin resistance, or central obesity. PAI-1 has been impli-
ated in cardiac remodeling (22), and recent observations in
ormal-weight mice with increased central obesity have
ndicated that tissue-level insulin resistance, vascular dys-
unction, adipocyte expression of PAI-1, and TNF-alpha
oexist and are reversible with anti–TNF-alpha therapy
30), suggesting a link among inflammation, central obesity,
nd cardiovascular dysfunction independent of obesity. Ul-
imately, cardiometabolic health may be more completely
escribed by integrating BMI with insulin resistance, fat
istribution, and inflammation, rather than by BMI alone.
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April 23, 2013:1698–706 Obesity, IR, and LV Remodeling in the MESA TrialPrevious observations from the MESA trial included
reported associations between inflammation and LV re-
modeling (14) or obesity, inflammation, and heart failure
incidence (15,31–33). In a study of 5,098 subjects with
cardiac MRI data in the MESA trial, Turkbey et al. (32)
reported an association between BMI and LV mass-to-
volume ratio, after adjustment for WHR and other clinical
risk markers. Of note, subjects with diabetes were included
in their population, and models were not adjusted for
measures of insulin resistance (e.g., fasting glucose, IFG, or
HOMA-IR). These results extend the prior investigations to
an even more pre-clinical population (without diabetes) to
directly address the impact of insulin resistance and central
obesity on concentric remodeling, suggesting that both BMI
and IFG may contribute to subclinical dysfunction (e.g., strain)
and concentric remodeling. Although our analysis was limited
to nondiabetic participants in the MESA trial, to allow for a
focus on an earlier cardiometabolic phenotype, it should be
pointed out that the effects of higher than median WHR were
still significant when the analysis included MESA participants
with diabetes (data not shown). Our results identified subjects
with increased cardiometabolic risk as at risk for incident heart
failure and as an important population to target for prevention.
Indeed, elevations in LV mass and concentric remodeling have
been associated with adverse outcome in the MESA trial (34).
Demonstrating that insulin resistance impacts LV remodeling
before clinical heart failure across BMI suggests that adoption
of more intensive strategies (e.g., bariatric surgery [26]) or
Figure 3 PAI-1 as a Function of Cardiometabolic Risk and Obes
Plasminogen activator inhibitor (PAI)-1 levels (log-transformed) across quartiles of
Comparisons across HOMA-IR and WHR groups made by Student t tests (with Bon
ations as in Figures 1 and 2. *p  0.05. **p  0.01. ***p  0.001.novel drug therapies (e.g., incretin modulation) in this high-risk group may improve outcome. Ultimately, BMI may not
the sole arbiter of cardiometabolic risk.
The results of this study must be viewed in light of its
cross-sectional design. Although measuring inflammation,
insulin resistance, and concentric LV remodeling at the
same time point renders difficult any suggestions of tempo-
ral sequence, the suggestion that insulin resistance may
influence hypertrophy and remodeling is biologically plau-
sible (35). Although correlations of LV structure and
functional parameters with inflammatory markers and insu-
lin resistance were modest, fully adjusted regression models
suggest a significant association of metabolic dysfunction
and LV remodeling. In addition, our adjustments for age,
sex, race, and other important markers of cardiometabolic
risk improved the robustness of any effects of these other
confounding variables on the association between insulin
resistance and concentric LV remodeling. Furthermore,
although formal glucose tolerance testing is considered
more prognostic than the parameters of cardiometabolic risk
used in this study (e.g., HOMA-IR, WHR, and IFG) (36),
it is not routinely performed in practice in all subjects, and
associations we observed here were in agreement with a
previous report using IFG (35). Finally, we recognize that
WHR is not an ideal marker of visceral adiposity, and more
advanced measures (e.g., computed tomography) may be
more specific. However, given that WHR is associated with
inflammation and remodeling independent of BMI, it is
likely that WHR more directly captures cardiometabolic
tratified by median WHR or HOMA-IR. Error bars represent 95% CI of the mean.
i adjustment for multiple hypothesis testing). n.s  not significant; other abbrevi-ity
BMI, s
ferrondisease relative to BMI.
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Obesity, IR, and LV Remodeling in the MESA Trial April 23, 2013:1698–706Conclusions
We demonstrated an association among insulin resistance,
central obesity, and concentric LV remodeling across BMI in
the MESA trial, independent of traditional and metabolic risk
factors. These results provide evidence to support the emerging
hypothesis that insulin resistance and central obesity mediate
concentric LV remodeling in otherwise healthy subjects be-
yond that predicted by BMI. Efforts to target subjects at higher
cardiometabolic risk, integrating assessments of insulin resis-
tance and WHR in addition to BMI may prevent further LV
remodeling and incident heart failure.
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APPENDIX
For an expanded list of references and a supplemental table,
please see the online version of this article.
